| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.0064 | 0.8 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | 0.046 | 0.8 |